In order to determine the role of TGF-β as a therapeutic biomarker for the effectiveness of losartan therapy on AoDR, we performed a sub-study of the COMPARE trial and revealed that TGF-β is an indirect effector of aortic dilatation. The gene discussed is TGFB1; the disease is Vascular dilatation.